Proper news from Britain - News from Britain you won’t find anywhere else. Not the tosh the big media force-feed you every day!
An AstraZeneca cancer drug received the green light by European regulators yesterday.
The London-listed drugs maker revealed that its bladder cancer treatment Imfinzi has been approved to treat adult patients in the European Union.
It comes amid reports that AstraZeneca – the FTSE 100's largest company – is considering moving its listing from the UK to the US in what would be a hammer blow to London's stock market.
The speculation was fuelled by the pharmaceutical sector's growing frustration with the UK's rules on approving medicines as well as a row over drug prices between the industry and the NHS.
Dave Fredrickson, head of AstraZeneca's oncology haematology unit, said: 'Imfinzi is poised to transform the standard of care for muscle-invasive bladder cancer in Europe.'
AstraZeneca shares edged up 1.3 per cent yesterday.
DIY INVESTING PLATFORMS
Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.
Compare the best investing account for you
Remove Ads